INNOVACAPNSEInnova Captab LimitedLowNeutral
Announced Thu, 7 May · 19:24 IST

Innova Captab Limited has informed the Exchange about Investor Presentation

Board & Shareholder Meetings View source PDF

INNOVACAP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.2%1-day move
₹866.00
prior close
₹850.75
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.1-1.3+1.7+1.3-1.2-0.3+0.0+0.4-0.6+1.0-0.8+0.1+14.2
Up moveDown movePending
AI summary

Innova Captab Limited released its investor presentation ahead of an earnings call scheduled for May 8, 2026, to discuss audited results for Q4 and FY ended March 31, 2026. The company reported FY26 revenue of ₹1,630 crore, up 31% YoY, with EBITDA of ₹250 crore (15.4% margin) and PAT of ₹141 crore (8.6% margin). Q4 FY26 was particularly strong with revenue of ₹447.8 crore, up 42% YoY. The company operates two segments – CDMO Services (₹1,133 crore revenue, 24% growth) and Branded Generics (₹497 crore revenue, 51% growth). The Jammu manufacturing plant in Kathua was commercialised in January 2025 and is ramping up well, contributing to capacity expansion. The company holds GMP certifications from UK-MHRA and PIC/S for its Baddi and Jammu facilities respectively, supporting its regulated market presence.

Likely market impact

Strong revenue growth of 31% YoY reflects robust execution across both CDMO and branded generics businesses. However, PAT margin compression to 8.6% from 10.3% YoY and negative free cash flow of ₹12.3 crore (due to capex investments) indicate near-term profitability pressure. The Jammu plant ramp-up and new regulatory certifications position the company for sustained long-term growth.